(Q26764867)

English

Tailored treatment options for patients with psoriatic arthritis and psoriasis: review of established and new biologic and small molecule therapies

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26892034%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

1 reference

14 November 2020

Tailored treatment options for patients with psoriatic arthritis and psoriasis: review of established and new biologic and small molecule therapies (English)

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26892034%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

psoriatic arthritis

4 references

12 March 2019

13 March 2019

17 June 2019

14 November 2020

4 references

12 March 2019

13 March 2019

17 June 2019

14 November 2020

disease-modifying antirheumatic drug

1 reference

14 November 2020

Coziana Ciurtin

3

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26892034%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

author name string

Sarah Elyoussfi

1

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26892034%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Benjamin J Thomas

2

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26892034%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

language of work or name

0 references

publication date

18 February 2016

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26892034%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

1 May 2016

1 reference

14 November 2020

Rheumatology International

5 references

12 March 2019

13 March 2019

17 June 2019

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26892034%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

14 November 2020

36

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26892034%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

5

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26892034%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

603-612

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26892034%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

copyright license

Creative Commons Attribution 4.0 International

4 references

Europe PubMed Central

12 March 2019

Europe PubMed Central

13 March 2019

Europe PubMed Central

17 June 2019

Europe PubMed Central

14 November 2020

copyright status

0 references

on focus list of Wikimedia project

0 references

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4839046

7 April 2017

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4839046

7 April 2017

Combination therapy of cyclosporine and anti-tumor necrosis factor α in psoriasis: a case series of 10 patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4839046

28 September 2017

Treatment of nail psoriasis: best practice recommendations from the Medical Board of the National Psoriasis Foundation.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4839046

28 September 2017

Improvements in productivity at paid work and within the household, and increased participation in daily activities after 24 weeks of certolizumab pegol treatment of patients with psoriatic arthritis: results of a phase 3 double-blind randomised pla

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4839046

28 September 2017

Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4839046

28 September 2017

Clinical efficacy, radiographic and safety findings through 5 years of subcutaneous golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of a randomised, placebo-controlled trial (the GO-REVEAL study).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4839046

28 September 2017

Efficacy and safety of itolizumab, a novel anti-CD6 monoclonal antibody, in patients with moderate to severe chronic plaque psoriasis: results of a double-blind, randomized, placebo-controlled, phase-III study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4839046

28 September 2017

Efficacy of tofacitinib, an oral janus kinase inhibitor, on clinical signs of moderate-to-severe plaque psoriasis in different body regions

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4839046

28 September 2017

Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4839046

28 September 2017

Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, pla

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4839046

28 September 2017

Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4839046

28 September 2017

Effect of certolizumab pegol on multiple facets of psoriatic arthritis as reported by patients: 24-week patient-reported outcome results of a phase III, multicenter study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4839046

28 September 2017

Effect of different imputation approaches on the evaluation of radiographic progression in patients with psoriatic arthritis: results of the RAPID-PsA 24-week phase III double-blind randomised placebo-controlled study of certolizumab pegol

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4839046

28 September 2017

Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4839046

28 September 2017

Assessment of short-term symptomatic efficacy of tocilizumab in ankylosing spondylitis: results of randomised, placebo-controlled trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4839046

28 September 2017

Direct and indirect comparison of the efficacy and safety of adalimumab, etanercept, infliximab and golimumab in psoriatic arthritis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4839046

28 September 2017

Switching between TNF inhibitors in psoriatic arthritis: data from the NOR-DMARD study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4839046

28 September 2017

Anti-tumor necrosis factor (TNF) drugs for the treatment of psoriatic arthritis: an indirect comparison meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4839046

28 September 2017

Infliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naive patients: the RESPOND study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4839046

28 September 2017

European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4839046

28 September 2017

A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4839046

28 September 2017

Adalimumab for treatment of moderate to severe chronic plaque psoriasis of the hands and feet: efficacy and safety results from REACH, a randomized, placebo-controlled, double-blind trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4839046

28 September 2017

Responses to adalimumab in patients with active psoriatic arthritis who have not adequately responded to prior therapy: effectiveness and safety results from an open-label study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4839046

28 September 2017

Infliximab monotherapy in Japanese patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. A randomized, double-blind, placebo-controlled multicenter trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4839046

28 September 2017

Efficacy and Safety of Efalizumab in Patients with Moderate-to-Severe Plaque Psoriasis Resistant to Previous Anti-Psoriatic Treatment: Results of a Multicentre, Open-label, Phase IIIb/IV Trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4839046

28 September 2017

Comparison of effectiveness and safety of infliximab, etanercept, and adalimumab in psoriatic arthritis patients who experienced an inadequate response to previous disease-modifying antirheumatic drugs

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4839046

28 September 2017

Effectiveness of adalimumab in treating patients with active psoriatic arthritis and predictors of good clinical responses for arthritis, skin and nail lesions

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4839046

28 September 2017

Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4839046

28 September 2017

Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4839046

28 September 2017

Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4839046

28 September 2017

Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4839046

28 September 2017

Adalimumab improves joint-related and skin-related functional impairment in patients with psoriatic arthritis: patient-reported outcomes of the Adalimumab Effectiveness in Psoriatic Arthritis Trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4839046

28 September 2017

Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4839046

28 September 2017

Infliximab improves health related quality of life and physical function in patients with psoriatic arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4839046

28 September 2017

Safety and efficacy of brodalumab for psoriasis after 120 weeks of treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4839046

31 May 2018

A 24-week randomized clinical trial investigating the efficacy and safety of two doses of etanercept in nail psoriasis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4839046

31 May 2018

Effect of ustekinumab on physical function and health-related quality of life in patients with psoriatic arthritis: a randomized, placebo-controlled, phase II trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4839046

31 May 2018

Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4839046

31 May 2018

Impact of adalimumab treatment on patient-reported outcomes: results from a Phase III clinical trial in patients with moderate to severe plaque psoriasis.

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3436-0

21 January 2018

Clinical response, drug survival, and predictors thereof among 548 patients with psoriatic arthritis who switched tumor necrosis factor α inhibitor therapy: results from the Danish Nationwide DANBIO Registry

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3436-0

21 January 2018

Treatment of nail psoriasis with adalimumab: an open label unblinded study.

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3436-0

21 January 2018

Clinical manifestations and responsiveness to adalimumab are similar in patients with ankylosing spondylitis with and without concomitant psoriasis.

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3436-0

21 January 2018

A randomized trial of etanercept as monotherapy for psoriasis.

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3436-0

21 January 2018

Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial.

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3436-0

21 January 2018

Once-weekly administration of etanercept 50 mg improves patient-reported outcomes in patients with moderate-to-severe plaque psoriasis.

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3436-0

21 January 2018

Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial.

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3436-0

21 January 2018

Sustained improvement in joint pain and nail symptoms with etanercept therapy in patients with moderate-to-severe psoriasis.

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3436-0

21 January 2018

A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis.

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3436-0

21 January 2018

Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1).

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3436-0

21 January 2018

Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3436-0

21 January 2018

Treatment of psoriatic arthritis with tumor necrosis factor inhibitors: longer-term outcomes including enthesitis and dactylitis with golimumab treatment in the Longterm Extension of a Randomized, Placebo-controlled Study (GO-REVEAL).

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3436-0

21 January 2018

Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial.

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3436-0

21 January 2018

Treatment of active ankylosing spondylitis with abatacept: an open-label, 24-week pilot study.

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3436-0

21 January 2018

An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis.

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3436-0

21 January 2018

Clinical response to alefacept: results of a phase 3 study of intramuscular administration of alefacept in patients with chronic plaque psoriasis

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3436-0

21 January 2018

Improved health-related quality of life following a randomized controlled trial of alefacept treatment in patients with chronic plaque psoriasis

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3436-0

21 January 2018

Long-term efficacy and safety of itolizumab in patients with moderate-to-severe chronic plaque psoriasis: A double-blind, randomized-withdrawal, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3436-0

21 January 2018

Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3436-0

21 January 2018

Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years.

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3436-0

21 January 2018

Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial.

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3436-0

21 January 2018

Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial.

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3436-0

21 January 2018

Secukinumab in plaque psoriasis--results of two phase 3 trials.

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3436-0

21 January 2018

Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE).

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3436-0

21 January 2018

Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study.

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3436-0

21 January 2018

Anti–Interleukin-17 Monoclonal Antibody Ixekizumab in Chronic Plaque Psoriasis

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3436-0

21 January 2018

Towards international guidelines for the management of psoriatic arthritis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4839046

28 November 2018

Brodalumab, an Anti–Interleukin-17–Receptor Antibody for Psoriasis

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3436-0

21 January 2018

Ten-year drug survival of anti-TNF agents in the treatment of inflammatory arthritides

1 reference

https://pubmed.ncbi.nlm.nih.gov/26892034

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis through one year of treatment: Results from the induction and maintenance psoriatic arthritis clinical trial 2

1 reference

https://pubmed.ncbi.nlm.nih.gov/26892034

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety of ustekinumab for the treatment of moderate-to-severe psoriasis: a phase III, randomized, placebo-controlled trial in Taiwanese and Korean patients (PEARL)

1 reference

https://pubmed.ncbi.nlm.nih.gov/26892034

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis

1 reference

https://pubmed.ncbi.nlm.nih.gov/26892034

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction

1 reference

https://pubmed.ncbi.nlm.nih.gov/26892034

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Oral apremilast in the treatment of active psoriatic arthritis: results of a multicenter, randomized, double-blind, placebo-controlled study

1 reference

https://pubmed.ncbi.nlm.nih.gov/26892034

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The ACCEPT study: ustekinumab versus etanercept in moderate-to-severe psoriasis patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/26892034

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/26892034

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rituximab in psoriatic arthritis: an exploratory evaluation

1 reference

https://pubmed.ncbi.nlm.nih.gov/26892034

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with open-label extension

1 reference

https://pubmed.ncbi.nlm.nih.gov/26892034

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The efficacy and safety of infliximab in patients with plaque psoriasis who had an inadequate response to etanercept: results of a prospective, multicenter, open-label study

1 reference

https://pubmed.ncbi.nlm.nih.gov/26892034

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Improvement of scalp and nail lesions with ixekizumab in a phase 2 trial in patients with chronic plaque psoriasis

1 reference

https://pubmed.ncbi.nlm.nih.gov/26892034

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Alefacept in combination with methotrexate for the treatment of psoriatic arthritis: results of a randomized, double-blind, placebo-controlled study

1 reference

https://pubmed.ncbi.nlm.nih.gov/26892034

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/26892034

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/26892034

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Itolizumab provides sustained remission in plaque psoriasis: a 5-year follow-up experience

1 reference

https://pubmed.ncbi.nlm.nih.gov/26892034

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adalimumab or cyclosporine as monotherapy and in combination in severe psoriatic arthritis: results from a prospective 12-month nonrandomized unblinded clinical trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/26892034

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Secukinumab in psoriasis: randomized, controlled phase 3 trial results assessing the potential to improve treatment response in partial responders (STATURE)

1 reference

https://pubmed.ncbi.nlm.nih.gov/26892034

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab' certolizumab pegol: results of a phase II randomized, placebo-controlled trial with a re-treatment extension

1 reference

https://pubmed.ncbi.nlm.nih.gov/26892034

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ustekinumab improves nail disease in patients with moderate-to-severe psoriasis: results from PHOENIX 1

1 reference

https://pubmed.ncbi.nlm.nih.gov/26892034

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Etanercept as monotherapy in patients with psoriasis

1 reference

https://pubmed.ncbi.nlm.nih.gov/26892034

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT)

1 reference

https://pubmed.ncbi.nlm.nih.gov/26892034

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efalizumab for the treatment of psoriatic arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/26892034

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression

1 reference

https://pubmed.ncbi.nlm.nih.gov/26892034

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The effectiveness of a biologic agent on axial manifestations of psoriatic arthritis. A twelve months observational study in a group of patients treated with etanercept

1 reference

https://pubmed.ncbi.nlm.nih.gov/26892034

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00296-016-3436-0

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26892034%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Dimensions Publication ID

0 references

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26892034%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26892034%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q26764867&oldid=2177106545"